Further investigations into the negative predictive value of 11q14 in placebo-controlled studies, such as the NSABP B-14, are required to confirm the role of RSF1 amplification as a biomarker of negative predictive value for tamoxifen benefit in the adjuvant setting in early breast cancer. This evidence concerns the gene RSF1 and breast cancer.